drugset / Trial / NCT05282420
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
RandomizedParallel-groupSingle-blindTreatment
Summary
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old
Timeline
- Start
- 2021-02-01
- Primary completion
- 2022-04-01
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |